Worldwide CINV Treatment (5-HT3 Inhibitors, NK1 Inhibitors, Others) Industry Insights, 2020 to 2025 – Yahoo Finance

DUBLIN, Feb. 26, 2020 /PRNewswire/ -- The "CINV Treatment Market - Growth, Trends, and Forecast (2020 - 2025)" report has been added to ResearchAndMarkets.com's offering.

Research and Markets Logo

The global CINV treatment market studied was projected to grow with a CAGR of nearly 5.8% over the forecast period.

The major factors attributing to the growth of the market are the increasing prevalence of cancer and rising research and development activities for cancer. According to the National Institutes of Health (NIH), in 2018, an estimated 1,735,350 new cases of cancer will be detected in the United States and 609,640 people will die from the disease.

Furthermore, the growing investments in research and development programs by the biotechnology and pharmaceutical companies is boosting the market growth. However, the lack of awareness of the available drugs is the major drawback for market growth.

Key Market Trends

Speciality Clinics Segment is Expected to Grow at a Faster Rate in the Forecast Period

When chemotherapy penetrates the body, sensors in the digestive system and brain detect its presence as a foreign substance. Several substances, including serotonin and substance P, are released, triggering nausea and vomiting reflex. This is the body's effort to get rid of the foreign substance. So the doctors prescribe treatment for the CINV.

The major factor boosting the market growth of the segment is the increasing number of cancer cases globally. As the patient pool increases, there is a growth of chemotherapy and its side effects. The oncology clinics are increasing in number and so does the market growth.North America Dominates the Market and Expected to do Same in the Forecast Period

North America is expected to dominate the overall CINV treatment market, throughout the forecast period. The market growth is due to factors such as the presence of key players, high prevalence of cancer patients in the region, established healthcare infrastructure, and availability of branded drugs are some of the key factors accountable for its large share in the market.

Furthermore, beneficial government initiatives and an increase in the number of research partnerships are some of the drivers expected to increase market growth. In the North America region, the United States holds the largest market share due to the factors such as the increasing number of geriatric populations, along with a growing number of patient pools in the country.

Competitive Landscape

The CINV Treatment market is moderately competitive and consists of several major players. Some of the companies which are currently dominating the market Merck & Co., Inc., GlaxoSmithKline plc, Heron Therapeutics, Inc., Helsinn Holding S.A., Baxter Healthcare, Sandoz (Novartis AG), Orchid Healthcare, Mylan Pharmaceuticals, Inc., Teva Pharmaceuticals, and Sun Pharma.

Key Topics Covered

1 INTRODUCTION1.1 Study Deliverables1.2 Study Assumptions1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS4.1 Market Overview4.2 Market Drivers4.2.1 Increasing Prevalence of Cancer4.2.2 Rising Research & Development Activities for Cancer Treatments4.3 Market Restraints4.3.1 Lack of Awareness of the Available Drugs4.4 Porter's Five Force Analysis4.4.1 Threat of New Entrants4.4.2 Bargaining Power of Buyers/Consumers4.4.3 Bargaining Power of Suppliers4.4.4 Threat of Substitute Products4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION5.1 By Drug Type5.1.1 5-HT3 inhibitors5.1.2 NK1 inhibitors5.1.3 Others5.2 By End-user5.2.1 Hospitals5.2.2 Specialty Clinics5.2.3 Others5.3 Geography5.3.1 North America5.3.1.1 United States5.3.1.2 Canada5.3.1.3 Mexico5.3.2 Europe5.3.2.1 Germany5.3.2.2 United Kingdom5.3.2.3 France5.3.2.4 Italy5.3.2.5 Spain5.3.2.6 Rest of Europe5.3.3 Asia-Pacific5.3.3.1 China5.3.3.2 Japan5.3.3.3 India5.3.3.4 Australia5.3.3.5 South Korea5.3.3.6 Rest of Asia-Pacific5.3.4 Middle-East and Africa5.3.4.1 GCC5.3.4.2 South Africa5.3.4.3 Rest of Middle-East and Africa5.3.5 South America5.3.5.1 Brazil5.3.5.2 Argentina5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE6.1 Company Profiles6.1.1 Merck & Co. Inc.6.1.2 GlaxoSmithKline plc6.1.3 Heron Therapeutics Inc.6.1.4 Helsinn Holding S.A.6.1.5 Novartis AG6.1.6 Baxter Healthcare6.1.7 Orchid Healthcare6.1.8 Mylan Pharmaceuticals Inc.6.1.9 Sun Pharmaceutical Industries Ltd.6.1.10 Teva Pharmaceutical Industries Ltd.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

For more information about this report visit https://www.researchandmarkets.com/r/71xkzw

Story continues

Original post:
Worldwide CINV Treatment (5-HT3 Inhibitors, NK1 Inhibitors, Others) Industry Insights, 2020 to 2025 - Yahoo Finance